MX2016013741A - Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. - Google Patents

Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.

Info

Publication number
MX2016013741A
MX2016013741A MX2016013741A MX2016013741A MX2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A
Authority
MX
Mexico
Prior art keywords
parkinson
patient
disease
rapid relief
motor fluctuations
Prior art date
Application number
MX2016013741A
Other languages
English (en)
Inventor
Michael M Lipp
Martin Freed
Richard P Batycky
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MX2016013741A publication Critical patent/MX2016013741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento períodos INACTIVOS en pacientes con la Enfermedad de Parkinson que comprenden la administración de levopoda en el sistema pulmonar de un paciente en donde posterior a la administración, mejora la puntuación de la Escala de Evaluación Unificada de la Enfermedad Parkinson (UPDRS) Parte 3 del paciente, por ejemplo, por al menos unos 5 puntos en comparación con el placebo control y/o en comparación con la puntuación de UPDRS III del paciente previo a la administración. La invención también proporciona métodos de reducción del promedio diaria de tiempo INACTIVO en un paciente con Parkinson.
MX2016013741A 2014-04-21 2014-04-21 Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. MX2016013741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Publications (1)

Publication Number Publication Date
MX2016013741A true MX2016013741A (es) 2017-04-06

Family

ID=54332876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013741A MX2016013741A (es) 2014-04-21 2014-04-21 Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.

Country Status (14)

Country Link
US (2) US20170296498A1 (es)
EP (2) EP3134077A4 (es)
JP (1) JP2017513866A (es)
KR (2) KR20210144946A (es)
CN (2) CN106659685B (es)
AU (2) AU2014391721B2 (es)
BR (1) BR112016024502A8 (es)
CA (1) CA2946165C (es)
IL (2) IL309959A (es)
MX (1) MX2016013741A (es)
RU (1) RU2698330C2 (es)
SG (1) SG11201608608PA (es)
WO (1) WO2015163840A1 (es)
ZA (1) ZA201607833B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
AU2019205327A1 (en) * 2018-01-05 2020-07-30 Impel Pharmaceuticals Inc. Intranasal delivery of levodopa powder by precision olfactory device
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
HUE031167T2 (hu) * 2002-03-20 2017-07-28 Civitas Therapeutics Inc A levodopa pulmonális bejuttatása
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
WO2010000763A2 (en) * 2008-06-30 2010-01-07 Novartis Ag Combination products
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
MX2021014782A (es) * 2012-10-22 2023-03-23 Civitas Therapeutics Inc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
EP3134077A1 (en) 2017-03-01
US20170296498A1 (en) 2017-10-19
CN113209055A (zh) 2021-08-06
BR112016024502A2 (pt) 2017-08-15
IL248445A0 (en) 2016-12-29
RU2016144340A3 (es) 2018-05-22
ZA201607833B (en) 2018-08-29
WO2015163840A1 (en) 2015-10-29
IL309959A (en) 2024-03-01
BR112016024502A8 (pt) 2021-06-29
RU2698330C2 (ru) 2019-08-26
CA2946165C (en) 2022-10-18
JP2017513866A (ja) 2017-06-01
CN106659685A (zh) 2017-05-10
AU2014391721A1 (en) 2016-11-03
CA2946165A1 (en) 2015-10-29
AU2020239754A1 (en) 2021-01-14
EP3134077A4 (en) 2017-12-20
AU2014391721B2 (en) 2020-07-16
SG11201608608PA (en) 2016-11-29
CN106659685B (zh) 2021-02-05
US20230053976A1 (en) 2023-02-23
KR20210144946A (ko) 2021-11-30
RU2016144340A (ru) 2018-05-22
AU2020239754B2 (en) 2022-06-23
EP3831375A1 (en) 2021-06-09
KR20170008754A (ko) 2017-01-24

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX2015012515A (es) Sistemas y métodos para el diseño y fabricación de calzado de protección de pacientes.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MY179105A (en) Methods of treating alzheimer's disease
PH12018501072A1 (en) Modified release orally administered amino acid formulations
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
EA201992832A1 (ru) Подкожное введение adamts13
MX2019003710A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX2018005028A (es) Composicion para el cuidado de la piel y metodos para la misma.
MX2016013741A (es) Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.
MX2019000677A (es) Células miméticas de células b.
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
SG11201903834XA (en) Medical skin external preparation
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
MX2015017129A (es) Uso de acetato de leuprolida como neurorregenerador.
MX2016001802A (es) Actividad cicatrizante de nanomateriales de hidroxiapatita con extracto de thl-80.